HUE059916T2 - Genetikailag módosított cannabis sativa növények és módosított kannabinoid vegyületek a kábítószer-függõség és más rendellenességek kezelésére - Google Patents
Genetikailag módosított cannabis sativa növények és módosított kannabinoid vegyületek a kábítószer-függõség és más rendellenességek kezeléséreInfo
- Publication number
- HUE059916T2 HUE059916T2 HUE19756525A HUE19756525A HUE059916T2 HU E059916 T2 HUE059916 T2 HU E059916T2 HU E19756525 A HUE19756525 A HU E19756525A HU E19756525 A HUE19756525 A HU E19756525A HU E059916 T2 HUE059916 T2 HU E059916T2
- Authority
- HU
- Hungary
- Prior art keywords
- disorders
- treatment
- modified
- cannabis sativa
- substance addiction
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
- A01H1/00—Processes for modifying genotypes ; Plants characterised by associated natural traits
- A01H1/06—Processes for producing mutations, e.g. treatment with chemicals or with radiation
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
- A01H6/00—Angiosperms, i.e. flowering plants, characterised by their botanic taxonomy
- A01H6/28—Cannabaceae, e.g. cannabis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/23—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y121/00—Oxidoreductases acting on X-H and Y-H to form an X-Y bond (1.21)
- C12Y121/03—Oxidoreductases acting on X-H and Y-H to form an X-Y bond (1.21) with oxygen as acceptor (1.21.3)
- C12Y121/03007—Tetrahydrocannabinolic acid synthase (1.21.3.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y121/00—Oxidoreductases acting on X-H and Y-H to form an X-Y bond (1.21)
- C12Y121/03—Oxidoreductases acting on X-H and Y-H to form an X-Y bond (1.21) with oxygen as acceptor (1.21.3)
- C12Y121/03008—Cannabidiolic acid synthase (1.21.3.8)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Botany (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nutrition Science (AREA)
- Developmental Biology & Embryology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862632448P | 2018-02-20 | 2018-02-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE059916T2 true HUE059916T2 (hu) | 2023-01-28 |
Family
ID=67687826
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE19756525A HUE059916T2 (hu) | 2018-02-20 | 2019-02-11 | Genetikailag módosított cannabis sativa növények és módosított kannabinoid vegyületek a kábítószer-függõség és más rendellenességek kezelésére |
HUE21171866A HUE060229T2 (hu) | 2018-02-20 | 2019-02-11 | Genetikailag módosított cannabis sativa növények és módosított kannabinoid vegyületek a kábítószer-függõség és más rendellenességek kezelésére |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE21171866A HUE060229T2 (hu) | 2018-02-20 | 2019-02-11 | Genetikailag módosított cannabis sativa növények és módosított kannabinoid vegyületek a kábítószer-függõség és más rendellenességek kezelésére |
Country Status (13)
Country | Link |
---|---|
US (4) | US11085047B2 (hu) |
EP (2) | EP3884936B1 (hu) |
JP (2) | JP7293561B2 (hu) |
KR (2) | KR102332631B1 (hu) |
CN (2) | CN113264914A (hu) |
AU (2) | AU2019225717B2 (hu) |
CA (2) | CA3120993C (hu) |
ES (2) | ES2929366T3 (hu) |
HU (2) | HUE059916T2 (hu) |
IL (2) | IL276518B (hu) |
PL (2) | PL3755318T3 (hu) |
PT (2) | PT3755318T (hu) |
WO (1) | WO2019164689A1 (hu) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4938547B2 (ja) | 2007-05-10 | 2012-05-23 | 日本トムソン株式会社 | 内面シールを備えた直動案内ユニット |
WO2022103639A1 (en) * | 2020-11-16 | 2022-05-19 | Orcosa Inc. | Methods of treating autoimmune or inflammatory conditions with cannabidiol or its derivatives/analogs |
US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
CN113099973B (zh) * | 2021-05-17 | 2022-05-27 | 潍坊市华以农业科技有限公司 | 一种药用大麻矮化高产的种植方法 |
EP4436559A1 (en) * | 2021-11-27 | 2024-10-02 | Miralogx LLC | Synthetic cannabinoid compounds, pharmaceutical compositions, and treatment methods |
WO2023150347A2 (en) * | 2022-02-07 | 2023-08-10 | Miralogx Llc | Synthetic cannabinoid compounds, pharmaceutical compositions, and treatment methods |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5942244A (en) | 1997-07-31 | 1999-08-24 | Farmo-Nat Ltd. | Local oral herbal slow release tablets |
GB2438682A (en) * | 2006-06-01 | 2007-12-05 | Gw Pharma Ltd | New use for cannabinoids |
DE102007046086A1 (de) * | 2007-09-26 | 2009-04-09 | Heinz Prof. Dr. Letzel | Pflanzenextrakt aus THC-armen Cannabis zur Behandlung von Erkrankungen |
GB2456183A (en) * | 2008-01-04 | 2009-07-08 | Gw Pharma Ltd | Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament |
US8884100B2 (en) | 2009-08-12 | 2014-11-11 | National Research Council Of Canada | Aromatic prenyltransferase from Cannabis |
GB2478595B (en) * | 2010-03-12 | 2018-04-04 | Gw Pharma Ltd | Phytocannabinoids in the treatment of glioma |
GB201111261D0 (en) * | 2011-07-01 | 2011-08-17 | Gw Pharma Ltd | Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders |
GB201117956D0 (en) * | 2011-10-18 | 2011-11-30 | Otsuka Pharma Co Ltd | Phytocannabinoids for use in the treatment of breast cancer |
US20160108016A1 (en) * | 2012-09-06 | 2016-04-21 | Northeastern University | Novel Cannabinergic Compounds and Uses Thereof |
CA3130696A1 (en) * | 2014-06-27 | 2015-12-30 | National Research Council Of Canada | Cannabichromenic acid synthase from cannabis sativa |
US20160000843A1 (en) * | 2014-07-01 | 2016-01-07 | MJAR Holdings, LLC | High cannabidiol cannabis strains |
BR112017015536B1 (pt) * | 2015-01-22 | 2021-05-18 | Phytoplant Research S.L | métodos de purificação de canabinoides |
US20160228385A1 (en) * | 2015-02-05 | 2016-08-11 | Colorado Can Llc | Purified cbd and cbda, and methods, compositions and products employing cbd or cbda |
US10934554B2 (en) * | 2015-05-28 | 2021-03-02 | Tweed, Inc. | Cannabis plants having modified expression of THCA synthase |
US10059683B2 (en) * | 2015-07-10 | 2018-08-28 | Noramco, Inc. | Process for the production of cannabidiol and delta-9-tetrahydrocannabinol |
AU2017313843A1 (en) * | 2016-08-18 | 2019-03-07 | Canopy Growth Corporation | Plants and methods for increasing and decreasing synthesis of cannabinoids |
-
2019
- 2019-02-11 PL PL19756525.2T patent/PL3755318T3/pl unknown
- 2019-02-11 CA CA3120993A patent/CA3120993C/en active Active
- 2019-02-11 AU AU2019225717A patent/AU2019225717B2/en active Active
- 2019-02-11 PT PT197565252T patent/PT3755318T/pt unknown
- 2019-02-11 KR KR1020207026914A patent/KR102332631B1/ko active IP Right Grant
- 2019-02-11 HU HUE19756525A patent/HUE059916T2/hu unknown
- 2019-02-11 US US16/612,472 patent/US11085047B2/en active Active
- 2019-02-11 ES ES21171866T patent/ES2929366T3/es active Active
- 2019-02-11 JP JP2020553539A patent/JP7293561B2/ja active Active
- 2019-02-11 EP EP21171866.3A patent/EP3884936B1/en active Active
- 2019-02-11 ES ES19756525T patent/ES2926328T3/es active Active
- 2019-02-11 PT PT211718663T patent/PT3884936T/pt unknown
- 2019-02-11 KR KR1020217013642A patent/KR102374793B1/ko active IP Right Grant
- 2019-02-11 HU HUE21171866A patent/HUE060229T2/hu unknown
- 2019-02-11 CN CN202110459283.6A patent/CN113264914A/zh active Pending
- 2019-02-11 WO PCT/US2019/017433 patent/WO2019164689A1/en active Search and Examination
- 2019-02-11 CA CA3091776A patent/CA3091776C/en active Active
- 2019-02-11 PL PL21171866.3T patent/PL3884936T3/pl unknown
- 2019-02-11 CN CN201980014261.XA patent/CN112040942A/zh active Pending
- 2019-02-11 EP EP19756525.2A patent/EP3755318B1/en active Active
-
2020
- 2020-01-10 US US16/739,219 patent/US10787675B2/en active Active
- 2020-08-05 IL IL276518A patent/IL276518B/en active IP Right Grant
-
2021
- 2021-04-14 IL IL282342A patent/IL282342B/en unknown
- 2021-04-15 AU AU2021202296A patent/AU2021202296B2/en active Active
- 2021-04-19 JP JP2021070269A patent/JP7322353B2/ja active Active
- 2021-07-22 US US17/383,119 patent/US11629355B2/en active Active
-
2023
- 2023-02-20 US US18/111,822 patent/US20230212597A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL282342B (en) | Genetically Modified Cannabis Sativa Plants and Modified Cannabinoid Compounds for the Treatment of Substance Addiction and Other Disorders | |
ZA201900986B (en) | Plants and methods for increasing and decreasing synthesis of cannabinoids | |
IL272627A (en) | Terpene-enriched cannabinoid compositions and method of treatment | |
IL304526A (en) | Production of compounds and preparations to inhibit the activity of shp2 | |
IL298689B1 (en) | Preparations and methods for suppressing masp-3 for the treatment of various diseases and conditions | |
IL284387A (en) | A medical product that includes cannabinoid, terpene and herbs | |
EP3526319A4 (en) | METHOD AND COMPOSITIONS AND FOR TREATING DISEASES AND DISORDERS OF THE CENTRAL VENTILATION SYSTEM | |
IL269302A (en) | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders | |
EP3615657A4 (en) | APPARATUS, METHODS AND COMPOSITION FOR THE SYNTHESIS OF CANNABINOID COMPOUNDS | |
EP3712130A4 (en) | METHOD OF SYNTHESIS OF ROXADUSTATE AND INTERMEDIATE COMPOUNDS THEREOF | |
IL272321A (en) | Methods and compositions for treating diseases of amyloid deposition | |
PT3611171T (pt) | Método para a síntese de eliglustato e dos seus compostos intermédios | |
EP3681477A4 (en) | IMPROVED METHOD AND COMPOSITION FOR THE TREATMENT OF CONDITIONS, DISEASES OR DISORDERS SENSITIVE TO TRITERPENES | |
EP3703706A4 (en) | COMPOSITIONS AND METHOD FOR TREATING ACID-BASE DISORDERS | |
IL269390A (en) | Preparations and methods for the treatment of parasitic diseases | |
IL291735A (en) | Heteroarylbiphenylamines for the treatment of pd-l1 diseases | |
PL3651586T3 (pl) | Sposób izolacji białka z materiału roślinnego | |
IL269179A (en) | Method for monitoring treatment of neuropsychiatric disorders | |
IL275653A (en) | Purified cannabis extracts and methods for their preparation | |
IL259674B (en) | Benzofuran derivatives for the treatment of diseases related to the central nervous system and other diseases | |
IL292086A (en) | Methods for the preparation of female cannabis sativa seed and preparations thereof | |
IL283201A (en) | Process and compounds for preparation of cannabinoids | |
IL284112A (en) | A method for extracting proteins from cannabis plant material | |
IL275941B (en) | Physical means and methods for affecting cannabis plants | |
EP3621945A4 (en) | STYLE DERIVATIVES FOR THE TREATMENT OF THE CNS AND OTHER DISEASES |